HIV Treatment
EACS 2017: Boosted Protease Inhibitor + Lamivudine Effective for HIV Maintenance Treatment
- Details
- Category: HIV Treatment
- Published on Tuesday, 31 October 2017 00:00
- Written by Keith Alcorn
HIV maintenance treatment with 2 drugs, a boosted protease inhibitor and lamivudine, is just as effective as 3-drug treatment with a boosted protease inhibitor for people who already have fully suppressed viral load, according to a meta-analysis of clinical trials presented last weekat the 16th European AIDS Conference (EACS 2017) in Milan.
EACS 2017: ABX464 Reduces HIV Reservoir But Does Not Delay Vial Rebound
- Details
- Category: HIV Treatment
- Published on Tuesday, 31 October 2017 00:00
- Written by Keith Alcorn
ABX464, a new drug that stimulates the clearance of HIV from infected cells, reduces the reservoir of HIV DNA in the body but does not delay the rebound of viral load when antiretroviral treatment is interrupted, Linos Vandekerckhove of the University of Ghent reported at the 16th European AIDS Conference (EACS 2017) last week in Milan.
EACS 2017: How a London Clinic Reduced New HIV Infections by 90%
- Details
- Category: Search for a Cure
- Published on Friday, 27 October 2017 00:00
- Written by Keith Alcorn
Scaling up HIV testing to reduce undiagnosed HIV infection requires a fundamental re-ordering of HIV testing services to make them more attractive to people at risk, and doing so can bring about enormous changes in HIV incidence and treatment uptake, delegates heard on the opening day of the 16th European AIDS Conference (EACS 2017) in Milan in October.
EACS 2017: Symtuza as Effective as Multi-Pill Combination in Previously Untreated People with HIV
- Details
- Category: HIV Treatment
- Published on Sunday, 29 October 2017 00:00
- Written by Keith Alcorn
The single-pill combination of darunavir, cobicistat, tenofovir alafenamide, and emtricitabine (Symtuza) is just as effective as a multi-pill combination of darunavir, cobicistat, emtricitabine, and the older tenofovir disoproxil fumarate formulation in previously untreated people with HIV, Chloe Orkin of the Royal London Hospital reported at the recet 16th European AIDS Conference (EACS 2017) in Milan.
IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
- Details
- Category: Search for a Cure
- Published on Thursday, 12 October 2017 00:00
- Written by Gus Cairns
For the last few years, a specialist symposium on HIV cure research has preceded the annual International AIDS Society meetings, and this year was no exception, with a 2-day forum at the Curie Institute in Paris before the opening of the 9th IAS Conference on HIV Science (IAS 2017).
More Articles...
- IDWeek 2017: Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV
- IDWeek 2017: Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year
- IAS 2017: Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
- IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
Web Design and Development by